The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study
Open accessAbstract
Background Rare cancers pose challenges for diagnosis, treatments, and clinical decision making. Information about rare cancers is scant. The RARECARE project defined rare cancers as those with an annual incidence of less than six per 100 000 people in European Union (EU). We updated the estimates of the burden of rare cancers in Europe, their time trends in incidence and survival, and provide information about centralisation of treatments in seven European countries.Methods We analysed data from 94 cancer registries for more than 2 million rare cancer diagnoses, to estimate European incidence and survival in 2000-07 and the corresponding time trends during 1995-2007. Incidence was calculated as the number of new cases divided by the corresponding total person-years in the population. 5-year relative survival was calculated by the Ederer-2 method. Seven registries (Belgium, Bulgaria, Finland, Ireland, the Netherlands, Slovenia, and the Navarra region in Spain) provided additional data for hospitals treating about 220 000 cases diagnosed in 2000-07. We also calculated hospital volume admission as the number of treatments provided by each hospital rare cancer group sharing the same referral pattern.Findings Rare cancers accounted for 24% of all cancers diagnosed in the EU during 2000-07. The overall incidence rose annually by 0.5% (99·8% CI 0·3-0·8). 5-year relative survival for all rare cancers was 48·5% (95% CI 48·4 to 48·6), compared with 63·4% (95% CI 63·3 to 63·4) for all common cancers. 5-year relative survival increased (overall 2·9%, 95% CI 2·7 to 3·2), from 1999-2001 to 2007-09, and for most rare cancers, with the largest increases for haematological tumours and sarcomas. The amount of centralisation of rare cancer treatment varied widely between cancers and between countries. The Netherlands and Slovenia had the highest treatment volumes.Interpretation Our study benefits from the largest pool of population-based registries to estimate incidence and survival of about 200 rare cancers. Incidence trends can be explained by changes in known risk factors, improved diagnosis, and registration problems. Survival could be improved by early diagnosis, new treatments, and improved case management. The centralisation of treatment could be improved in the seven European countries we studied.Funding The European Commission (Chafea).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, translating the capabilities of current patch-based foundation models to address patient- and slide-level clinical challenges still remains complex due to the immense scale of gigapixel WSIs, compounded by the small size of patient cohorts in real-world evidence39–42, especially for rare diseases with limited training data43–45.”
From A multimodal whole-slide foundation model for pathology (2025) · cites this paper as [43]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Classification of Diseases for Oncology
National Cancer Institute (2020) · Definitions · doi:10.32388/1bjeus · Cited by 3,810
Angelis, R. D., Sant, M., Coleman, M. P., Francisci, S., Baili, P., Pierannunzio, D., Trama, A., Visser, O. J., Brenner, H., Ardanáz, E., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70546-1 · Cited by 1,888
Self-citationWorldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis
Vaccarella, S., Franceschi, S., Bray, F., Wild, C. P., Plummer, M., & Dal Maso, L. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1604412 · Cited by 1,145
Rare cancers are not so rare: The rare cancer burden in Europe
Gatta, G., van der Zwan, J. M., Casali, P. G., Siesling, S., Tos, A. P. D., Kunkler, I. H., Otter, R., Licitra, L. F., Mallone, S., Tavilla, A., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.08.008 · Cited by 813
Self-citationHuman papillomavirus related head and neck cancer survival: A systematic review and meta-analysis
O’Rorke, M. A., Ellison, M. V., Murray, L., Moran, M., James, J. A., & Anderson, L. A. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.06.019 · Cited by 422
Self-citationHeck, J. E., Berthiller, J., Vaccarella, S., Winn, D. M., Smith, E., Shangina, O., Schwartz, S. M., Purdue, M. P., Pilarska, A., Eluf‐Neto, J., et al. (2009) · International Journal of Epidemiology · doi:10.1093/ije/dyp350 · Cited by 385
Recent changes in the epidemiology of head and neck cancer
Curado, M. P., & Hashibe, M. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32832a68ca · Cited by 354
Kantarjian, H. M., O'Brien, S. M., Jabbour, E. J., Garcia‐Manero, G., Quintás‐Cardama, A., Shan, J., Rios, M. B., Ravandi, F., Faderl, S. H., Kadia, T. M., et al. (2012) · Blood · doi:10.1182/blood-2011-08-358135 · Cited by 335
Sant, M., Minicozzi, P., Mounier, M., Anderson, L. A., Brenner, H., Holleczek, B., Marcos‐Gragera, R., Maynadié, M., Monnereau, A., Osca‐Gelis, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70282-7 · Cited by 292
Self-citationLepage, C., Capocaccia, R., Hackl, M., Lemmens, V., Molina‐Montes, E., Pierannunzio, D., Sant, M., Trama, A., Faivre, J., Hackl, M., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.034 · Cited by 149
Self-citation
Research works printed but not linked: 1
- Ederer, 1961, The relative survival: a statistical methodology, Natl Cancer Inst Monogr, 6, 101
Cited by
Sorted by citations
Casali, P. G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I. P., Bovée, J. V. M. G., Brodowicz, T., Broto, J. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy096 · Cited by 1,615
Towards a general-purpose foundation model for computational pathology
Chen, R. J., Ding, T., Lu, M. Y., Williamson, D. F. K., Jaume, G., Song, A. H., Chen, B., Zhang, A., Shao, D., Shaban, M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02857-3 · Cited by 1,560
Gronchi, A., Miah, A. B., Dei Tos, A. P., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.07.006 · Cited by 1,115
Self-citationA visual-language foundation model for computational pathology
Lu, M. Y., Chen, B., Williamson, D. F. K., Chen, R. J., Liang, I., Ding, T., Jaume, G., Odintsov, I., Le, L. P., Gerber, G., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02856-4 · Cited by 966
Machiels, J.-P., Leemans, C. R., Golusiński, W., Grau, C., Licitra, L. F., & Grégoire, V. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.011 · Cited by 945
Strauss, S. J., Frezza, A. M., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., Bonvalot, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.1995 · Cited by 513
Self-citationThe present and future of the Cancer Dependency Map
Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W. C., & Vazquez, F. (2025) · Nature Reviews Cancer · doi:10.1038/s41568-024-00763-x · Cited by 454
Mosele, M. F., Westphalen, C. B., Stenzinger, A., Barlési, F., Bayle, A., Bièche, I., Bonastre, J., Castro, E., Dienstmann, R., Krämer, A., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.04.005 · Cited by 468
Why develop photoactivated chemotherapy?
Bonnet, S. A. (2018) · Dalton Transactions · doi:10.1039/c8dt01585f · Cited by 300
Pinieux, G. D. B. D., Karanian, M., Loarer, F. L., Guellec, S. L., Chabaud, S., Terrier, P., Bouvier, C., Batistella, M., Neuville, A., Robin, Y. M., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246958 · Cited by 274
Stacchiotti, S., Frezza, A. M., Blay, J., Baldini, E. H., Bonvalot, S., Bovée, J. V. M. G., Callegaro, D., Casali, P. G., Chiang, R. C.-J., Demetri, G. D., et al. (2021) · Cancer · doi:10.1002/cncr.33618 · Cited by 238
Self-citationvan Herpen, C., Poorten, V. V., Skálová, A., Terhaard, C. H. J., Maroldi, R., van Engen, A., BAUJAT, B., Locati, L. D., Jensen, A., Smeele, L. E., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100602 · Cited by 217
Self-citationActive targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics
Shi, P., Cheng, Z., Zhao, K., Chen, Y., Zhang, A., Gan, W., & Zhang, Y. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01826-1 · Cited by 216
Sørbye, H., Grande, E., Pavel, M., Tesselaar, M. E. T., Fazio, N., Reed, N. S., Knigge, U., Christ, E., Ambrosini, V., Couvelard, A., et al. (2023) · Journal of Neuroendocrinology · doi:10.1111/jne.13249 · Cited by 205
The NCI-MATCH trial: lessons for precision oncology
O'Dwyer, P. J., Gray, R. J., Flaherty, K. T., Chen, A. P., Li, S., Wang, V., McShane, L. M., Patton, D. R., Tricoli, J. V., Williams, P. M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02379-4 · Cited by 199
A multimodal whole-slide foundation model for pathology
Ding, T., Wagner, S. J., Song, A. H., Chen, R. J., Lu, M. Y., Zhang, A., Vaidya, A. J., Jaume, G., Shaban, M., Kim, A., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03982-3 · Cited by 171
“This is especially beneficial for rare cancers that affect fewer than 15 individuals per 100,000 annually 43–45 , for which pathologists can identify nonspecific malignancies based on similar WSIs and their corresponding pathology reports.”
Ferrari, A., Brecht, I. B., Gatta, G., Schneider, D. T., Orbach, D. H., Cecchetto, G., Godzinski, J. K., Réguerre, Y., Bień, E., Stachowicz‐Stencel, T., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.031 · Cited by 104
Self-citationChordoma: update on disease, epidemiology, biology and medical therapies
Frezza, A. M., Botta, L., Trama, A., Tos, A. P. D., & Stacchiotti, S. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000502 · Cited by 95
Self-citationSoomers, V. L. M. N., Husson, O., Young, R., Desar, I. M. E., & van der Graaf, W. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000592 · Cited by 95
Hoes, L. R., Henegouwen, J. M. V. B., van der Wijngaart, H., Zeverijn, L. J., Velden, D. L. V. D., van de Haar, J., Roepman, P., de Leng, W. W. J., Jansen, A. M. L., van Werkhoven, E. D., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3752 · Cited by 86
Morphological Prototyping for Unsupervised Slide Representation Learning in Computational Pathology
Song, A. H., Chen, R. J., Ding, T., Williamson, D. F. K., Jaume, G., & Mahmood, F. (2024) · 2024 IEEE/CVF Conference on Computer Vision and Pattern Recognition (CVPR) · doi:10.1109/cvpr52733.2024.01099 · Cited by 79
Epidemiology of rare cancers and inequalities in oncologic outcomes
Gatta, G., Trama, A., Capocaccia, R., Hackl, M., Eycken, E. V., Henau, K., Dimitrova, N., Šekerija, M., Dušek, L., Mägi, M., et al. (2017) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.08.018 · Cited by 76
Self-citationBock, S., Hoffmann, D. G., Jiang, Y., Chen, H., & Il’yasova, D. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17082710 · Cited by 73
UK guidelines for the management of bone sarcomas
Gerrand, C., Amary, F. M., Anwar, H. A., Brennan, B. M. D., Dileo, P., Kalkat, M. S., McCabe, M. G., McCullough, A. L., Parry, M., Patel, A., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02868-4 · Cited by 69
Kollár, A., Rothermundt, C. A., Klenke, F. M., Bode, B., Baumhoer, D., Arndt, V., & Feller, A. (2019) · Cancer Epidemiology · doi:10.1016/j.canep.2019.101596 · Cited by 66
Redaelli, S., Fossati, P., Stacchiotti, S., Akiyama, T., Asencio, J. M., Bandiera, S., Boglione, A., Boland, P. J., Bolle, S., Bruland, Ø. S., et al. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.04.028 · Cited by 64
Self-citationBig Data in Head and Neck Cancer
Resteghini, C., Trama, A., Borgonovi, E., Hosni, H., Corrao, G., Orlandi, E. M., Calareso, G., Cecco, L. D., Piazza, C., Mainardi, L. T., et al. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0585-2 · Cited by 62
Self-citationMachiels, J.-P., Leemans, C. R., Golusiński, W., Grau, C., Licitra, L. F., & Grégoire, V. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.105042 · Cited by 61
The future of tumor organoids in precision therapy
Kim, S., van de Wetering, M., Clevers, H. C., & Sanders, K. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.03.005 · Cited by 62
EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma
Papadouli, I., Mueller-Berghaus, J., Beuneu, C., Ali, S., Hofner, B., Pétavy, F., Tzogani, K., Miermont, A. M., Norga, K., Kholmanskikh, O., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0646 · Cited by 59
Off-Label Medication: From a Simple Concept to Complex Practical Aspects
Rusz, C.-M., Ősz, B.-E., Jîtcă, G., Miklos, A., Bătrînu, M.-G., & Imre, S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph181910447 · Cited by 58
Incidence and Survival of Patients With Conjunctival Melanoma in Europe
Virgili, G., Parravano, M., Gatta, G., Capocaccia, R., Mazzini, C., Mallone, S., Botta, L., & for the RARECAREnet Working Group (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.0531 · Cited by 58
Self-citationCrosstalk between CAFs and tumour cells in head and neck cancer
Li, X., González-Maroto, C., & Tavassoli, M. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02053-9 · Cited by 61
High-Grade Progression Confers Poor Survival in Pancreatic Neuroendocrine Tumors
Botling, J., Lamarca, Á., Bajic, D., Norlén, O., Lönngren, V., Kjaer, J., Eriksson, B. K., Welin, S., Hellman, P., Rindi, G., et al. (2019) · Neuroendocrinology · doi:10.1159/000504392 · Cited by 60
Trama, A., Bernasconi, A., McCabe, M. G., Guevara, M., Gatta, G., Botta, L., the RARECAREnet Working Group, Ries, L., & Bleyer, A. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27407 · Cited by 56
Self-citationImbimbo, M., Ottaviano, M., Vitali, M., Fabbri, A., Leuzzi, G., Fiore, M., Franceschini, D., Pasello, G., Perrino, M., Schiavon, M., et al. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.001 · Cited by 54
Self-citationUnmet supportive care needs of patients with rare cancer: A systematic review
de Heus, E., van der Zwan, J. M., Husson, O., Frissen, A., van Herpen, C. M. L., Merkx, M. A. W., & Duijts, S. F. A. (2021) · European Journal of Cancer Care · doi:10.1111/ecc.13502 · Cited by 52
Survival of adults with cancers of bone or soft tissue in Europe—Report from the EUROCARE-5 study
Stiller, C. A., Botta, L., Brewster, D., Ho, V. K. Y., Frezza, A. M., Whelan, J. S., Casali, P. G., Trama, A., & Gatta, G. (2018) · Cancer Epidemiology · doi:10.1016/j.canep.2018.08.010 · Cited by 51
Self-citationNetworking in rare cancers: What was done, what's next
Frezza, A. M., Trama, A., Blay, J., & Casali, P. G. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.03.030 · Cited by 47
Self-citationIncidence and survival of rare cancers in the US and Europe
Botta, L., Gatta, G., Trama, A., Bernasconi, A., Sharon, E., Capocaccia, R., Mariotto, A. B., & the RARECAREnet working group (2020) · Cancer Medicine · doi:10.1002/cam4.3137 · Cited by 47
Self-citationKlein, O., Senko, C., Carlino, M. S., Markman, B., Jackett, L. A., Gao, B., Lum, C., Kee, D., Behren, A., Palmer, J., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1908771 · Cited by 46
Risk of Rare Cancers Among Solid Organ Transplant Recipients
D’Arcy, M. E., Castenson, D., Lynch, C. F., Kahn, A. R., Morton, L. M., Shiels, M. S., Pfeiffer, R. M., & Engels, E. A. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa078 · Cited by 43
Blay, J., Casali, P. G., Bouvier, C., Dehais, C., Galloway, I., Gietema, J. A., Halámková, J., Hindi, N., Idbaïh, A., Kinloch, E., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100174 · Cited by 43
Self-citationWakamatsu, T., Ogawa, H., Yoshida, K., Matsuoka, Y., Shizuma, K., Imura, Y., Tamiya, H., Nakai, S., Yagi, T., Nagata, S., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.893592 · Cited by 43
Fausti, V., Vita, A. D., Vanni, S., Ghini, V., Gurrieri, L., Riva, N., Casadei, R., Maraldi, M., Ercolani, G., Cavaliere, D., et al. (2023) · Cancers · doi:10.3390/cancers15041080 · Cited by 41
de Heus, E., Duijts, S. F. A., van der Zwan, J. M., Kapiteijn, E., van Dijkum, E. J. M. N., van Herpen, C. M. L., & Merkx, M. A. W. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.03.001 · Cited by 40
Treatment challenges in and outside a network setting: Head and neck cancers
Orlandi, E. M., Alfieri, S., Simon, C., Trama, A., Licitra, L. F., Hackl, M., Eycken, E. V., Henau, K., Dimitrova, N., Šekerija, M., et al. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.02.007 · Cited by 39
Self-citationde Heus, E., Engelen, V., Dingemans, I., Richel, C., Schrieks, M., van der Zwan, J. M., Besselink, M. G., Henegouwen, M. I. V. B., van Herpen, C. M. L., & Duijts, S. F. A. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01886-2 · Cited by 38
Progress in Radiotherapy for Cholangiocarcinoma
Wang, N., Huang, A., Kuang, B., Yu, X., Xiao, Y., & Ma, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.868034 · Cited by 38
Dinmohamed, A. G., & Visser, O. J. (2019) · Stem Cell Investigation · doi:10.21037/sci.2019.10.03 · Cited by 37
Self-citationDrabbe, C., Grünhagen, D. J., van Houdt, W. J., Braam, P. M., Soomers, V. L. M. N., van der Hage, J. A., de Haan, J. J., Keymeulen, K., Husson, O., & van der Graaf, W. T. A. (2021) · Cancers · doi:10.3390/cancers13040679 · Cited by 37
Hunter, A. M., Newman, H., Dezern, A. E., Steensma, D. P., Niyongere, S., Roboz, G. J., Mo, Q., Chan, O., Gerds, A. T., Sallman, D. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0935 · Cited by 39
Delisle, M. E., Gyorki, D. E., Bonvalot, S., & Nessim, C. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12517-w · Cited by 37
Treatment challenges in and outside a network setting: Soft tissue sarcomas
Pasquali, S., Bonvalot, S., Tzanis, D., Casali, P. G., Trama, A., Gronchi, A., Hackl, M., Eycken, E. V., Henau, K., Dimitrova, N., et al. (2017) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.09.015 · Cited by 37
Self-citationPreoperative hypofractionated radiotherapy for soft tissue sarcomas: a systematic review
Roohani, S., Ehret, F., Kobus, M., Flörcken, A., Märdian, S., Striefler, J. K., Rau, D., Öllinger, R., Jarosch, A., Budach, V., et al. (2022) · Radiation Oncology · doi:10.1186/s13014-022-02072-9 · Cited by 36
Value and Quality of Care in Head and Neck Oncology
Takes, R. P., Halmos, G. B., Ridge, J. A., Bossi, P., Merkx, M. A. W., Rinaldo, A., Sanabria, Á., Smeele, L. E., Mäkitie, A. A., & Ferlito, A. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00952-5 · Cited by 36
Filippini, D. M., Carosi, F., Querzoli, G., Sabbioni, S., Fermi, M., Chiari, F., Gili, R., Pantaleo, M. A., Succo, G., Molteni, G., et al. (2025) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-025-09707-z · Cited by 34
Ferrari, A., Schneider, D. T., Bisogno, G., Réguerre, Y., Godzinski, J. K., Bień, E., Stachowicz‐Stencel, T., Cecchetto, G., Brennan, B. M. D., Roganović, J., et al. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.28993 · Cited by 34
An Overview of Advances in Rare Cancer Diagnosis and Treatment
Christyani, G., Carswell, M., Qin, S., & Kim, W. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021201 · Cited by 33
Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting
Ray-Coquard, I., Trama, A., Seckl, M., Fotopoulou, C., Pautier, P., Pignata, S., Kristensen, G. B., Mangili, G., Falconer, H., Massuger, L. F. A. G., et al. (2017) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.09.025 · Cited by 33
Self-citationBasket Trials for Intractable Cancer
Qin, B., Jiao, X., Liu, K., Wu, Y., He, X., Liu, J., Qin, W., Wang, Z., & Zang, Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00229 · Cited by 33
The European study on centralisation of childhood cancer treatment
Gatta, G., Botta, L., Comber, H., Dimitrova, N., Leinonen, M. K., Pritchard‐Jones, K., Siesling, S., Trama, A., Eycken, L. J. V., van der Zwan, J. M., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.024 · Cited by 32
Self-citationMultidisciplinary Management of Retroperitoneal Sarcoma: Diagnosis, Prognostic Factors and Treatment
Carbone, F., Pizzolorusso, A., Lorenzo, G. D., Marzo, M. D., Cannella, L., Barretta, M. L., Delrio, P., & Tafuto, S. (2021) · Cancers · doi:10.3390/cancers13164016 · Cited by 31
Trama, A., Badalamenti, G., Baldi, G. G., Brunello, A., Caira, M., Drove, N., Marrari, A., Palmerini, E., Vincenzi, B., Tos, A. P. D., et al. (2019) · Cancer Epidemiology · doi:10.1016/j.canep.2019.02.012 · Cited by 31
Self-citationRare cancers are not rare in Asia as well: The rare cancer burden in East Asia
Matsuda, T., Won, Y., Chiang, R. C.-J., Lim, J., Saika, K., Fukui, K., Lee, W., Botta, L., Bernasconi, A., & Trama, A. (2020) · Cancer Epidemiology · doi:10.1016/j.canep.2020.101702 · Cited by 31
Self-citationRethinking placebos: embracing synthetic control arms in clinical trials for rare tumors
Serrano, C., Rothschild, S., Villacampa, G. J., Heinrich, M. C., George, S., Blay, J., Sicklick, J. K., Schwartz, G. K., Rastogi, S., Jones, R. L., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02578-z · Cited by 30
Whelan, J. S., Hackshaw, A. K., McTiernan, A., Grimer, R. J., Spooner, D. A., Bate, J. M., Ranft, A., Paulussen, M., Juergens, H., Craft, A. W., et al. (2018) · Clinical Sarcoma Research · doi:10.1186/s13569-018-0093-y · Cited by 30
Blay, J., Casali, P. G., Ray-Coquard, I. L., Seckl, M. J., Gietema, J. A., de Herder, W. W., Caplin, M. E., Klümpen, H., Gléhen, O., Wyrwicz, L. S., et al. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.100861 · Cited by 29
Self-citationCabozantinib as an emerging treatment for sarcoma
Schöffski, P., Blay, J., & Ray-Coquard, I. L. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000644 · Cited by 29
Kondo, T. (2020) · Cancer Science · doi:10.1111/cas.14669 · Cited by 28
Sandrucci, S., Naredi, P. L. J., & Bonvalot, S. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.12.012 · Cited by 28
Bacterial pathogens in pediatric appendicitis: a comprehensive retrospective study
Felber, J., Gross, B., Rahrisch, A., Waltersbacher, E., Trips, E., Schröttner, P., Fitze, G., & Schultz, J. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1027769 · Cited by 27
Treatment challenges in and outside a network setting: Gastrointestinal neuroendocrine tumours
Laskaratos, F., & Caplin, M. E. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.03.012 · Cited by 27
Trama, A., Botta, L., Foschi, R., Visser, O. J., Borràs, J. M., Žagar, T., Primic‐Žakelj, M., Bella, F., Dimitrova, N., Gatta, G., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00837 · Cited by 27
Self-citationParathyroid Carcinoma: An Up-to-Date Retrospective Multicentric Analysis
Quaglino, F., Manfrino, L., Cestino, L., Giusti, M., Mazza, E., Piovesan, A., Palestini, N., Lauro, C., & Castellano, E. (2020) · International Journal of Endocrinology · doi:10.1155/2020/7048185 · Cited by 27
Cancer treatment data available in European cancer registries: Where are we and where are we going?
Giusti, F., Martos, C., Trama, A., Bettio, M., Sanvisens, A., Audisio, R. A., Arndt, V., Francisci, S., Dochez, C., Ribes, J., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1109978 · Cited by 27
Self-citationMalignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group
Remón, J., Nadal, E., Dómine, M., Ruffinelli, J. C., García, Y. G., Pardo, J. C., López, R., Ramos, Á. C., García‐Campelo, R., Martín, P., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.06.034 · Cited by 26
Current approaches to management of bone sarcoma in adolescent and young adult patients
Ingley, K. M., Maleddu, A., Grange, F. L., Gerrand, C., Bleyer, A., Yasmin, E., Whelan, J., & Strauss, S. J. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29442 · Cited by 26
Incidence of soft tissue sarcoma in Taiwan: A nationwide population-based study (2007–2013)
Hung, G., Horng, J., Chen, P. C.-H., Lin, L., Chen, J.-Y., Chuang, P., Chao, T., & Yen, C. (2019) · Cancer Epidemiology · doi:10.1016/j.canep.2019.04.007 · Cited by 26
Challenges of Systemic Therapy Investigations for Bone Sarcomas
Nakano, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073540 · Cited by 25
Tyrosine kinase inhibitors in sarcoma treatment (Review)
Kyriazoglou, A. I., Gkaralea, L. E., Kotsantis, I., Anastasiou, Μ., Pantazopoulos, A., Prevezanou, M., Chatzidakis, I., Kavourakis, G., Economopoulou, P., Nixon, I., et al. (2022) · Oncology Letters · doi:10.3892/ol.2022.13303 · Cited by 25
Troussard, X., Maître, E., & Paillassa, J. (2024) · American Journal of Hematology · doi:10.1002/ajh.27240 · Cited by 25
Self-citationDeng, X., Zhao, R., Tang, Y., Yi, M., Ge, Z., Wang, D., Fang, Q., Xiong, Z., Duan, A., Liu, W., et al. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c11749 · Cited by 24
Borgognoni, L., Pescitelli, L., Gerlini, G., Brandani, P., Gelli, R., Giannotti, V., Bellucci, F. B., & Sestini, S. (2020) · Anticancer Research · doi:10.21873/anticanres.14670 · Cited by 24
Mathoulin‐Pélissier, S., & Pritchard‐Jones, K. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.02.015 · Cited by 23
Pusceddu, S., Barretta, F., Trama, A., Botta, L., Milione, M., Buzzoni, R., de Braud, F., Mazzaferro, V., Pastorino, U., Seregni, E. C., et al. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0489 · Cited by 23
Self-citationMorfouace, M., Stevovic, A., Vinches, M., Golfinopoulos, V., Jin, D. X., Holmes, O., Erlich, R., Fayette, J., Croce, S., Ray-Coquard, I. L., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-001075 · Cited by 22
Salivary gland cancers in elderly patients: challenges and therapeutic strategies
Colombo, E. V., Lierde, C. V., Zlate, A., Jensen, A., Gatta, G., Didoné, F., Licitra, L. F., Grégoire, V., Poorten, V. V., & Locati, L. D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1032471 · Cited by 22
Self-citationSex Differences in Soft Tissue Sarcoma: Incidence, Clinicopathological Profile, Survival, and Costs
Buja, A., Rugge, M., Tropea, S., Cozzolino, C., Formaro, C. M., Grotto, G., Zorzi, M., Vecchiato, A., Fiore, P. D., Brunello, A., et al. (2023) · Journal of Women s Health · doi:10.1089/jwh.2023.0019 · Cited by 22
Self-citationCurrent status and perspectives of patient-derived rare cancer models
Kondo, T. (2020) · Human Cell · doi:10.1007/s13577-020-00391-1 · Cited by 21
Targeted therapy for rare lung cancers: Status, challenges, and prospects
Wang, C., Yuan, X., & Xue, J. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.05.007 · Cited by 21
Malignant ovarian and testicular germ cell tumors: Common characteristics but different prognoses
Sköld, C., Jansson, A. K., & Glimelius, I. C. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13778 · Cited by 21
Immunotherapy in malignant pleural mesothelioma: a review of literature data
Menis, J., Pasello, G., & Remón, J. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-673 · Cited by 21
Thomas, B., Bigdeli, A. K., Nolte, S., Gazyakan, E., Harhaus, L., Bischel, O. E., Lehner, B., Egerer, G., Mechtersheimer, G., Hohenberger, P., et al. (2022) · Cancers · doi:10.3390/cancers14174312 · Cited by 20
Global Burden of Rare Cancers: Insights from GLOBOCAN 2022 Estimates
Elmadani, M., Klara, S. M., Mustafa, M. Q., Kiptulon, E. K., & Máté, O. (2025) · Cancers · doi:10.3390/cancers17101721 · Cited by 20
Ghosal, S., Das, S., Pang, Y. K., Gonzales, M. K., Huynh, T., Yang, Y., Taïeb, D., Crona, J., Shankavaram, U. T., & Pacák, K. (2019) · International Journal of Cancer · doi:10.1002/ijc.32654 · Cited by 21
A multidisciplinary approach to soft-tissue sarcoma of the extremities
Nakayama, R. T., Mori, T., Okita, Y., Shiraishi, Y., & Endo, M. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1814150 · Cited by 20
Biology-guided precision medicine in rare cancers: Lessons from sarcomas and neuroendocrine tumours
van der Graaf, W. T. A., Tesselaar, M. E. T., McVeigh, T. P., Oyen, W. J. G., & Fröhling, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.011 · Cited by 20
Rosell, L., Wihl, J., Nilbert, M. C., & Malmström, M. (2020) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s240140 · Cited by 20
Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting
Imbimbo, M., Maury, J., Garassino, M. C., Girard, N., Hackl, M., Eycken, E. V., Henau, K., Dimitrova, N., Šekerija, M., Dušek, L., et al. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.01.078 · Cited by 19
Self-citation
Metadata
- Authors
- Gatta, G., Capocaccia, R., Botta, L., Mallone, S., De Angelis, R., Ardanaz, E., Comber, H., Dimitrova, N., Leinonen, M. K., Siesling, S., van der Zwan, J. M., Van Eycken, L., Visser, O., Žakelj, M. P., Anderson, L. A., Bella, F., Kaire, I., Otter, R., Stiller, C. A., Trama, A., Hackl, M., Henau, K., Van Damme, N., Valerianova, Z., Sekerija, M., Dušek, L., Mägi, M., Paapsi, K., Malila, N., Velten, M., Troussard, X., Bouvier, V., Guizard, A.-V., Bouvier, A.-M., Arveux, P., Maynadié, M., Woronoff, A.-S., Robaszkiewicz, M., Baldi, I., Monnereau, A., Tretarre, B., Colonna, M., Molinié, F., Bara, S., Schvartz, C., Lapôtre-Ledoux, B., Grosclaude, P., Stabenow, R., Luttmann, S., Nennecke, A., Engel, J., SchubertFritschle, G., Heidrich, J., Holleczek, B., Jónasson, J. G., Clough-Gorr, K., Mazzoleni, G., Giacomin, A., Sardo, A. S., Barchielli, A., Serraino, D., Collarile, P., Pannozzo, F., Ricci, P., Autelitano, M., Spagnoli, G., Fusco, M., Usala, M., Vitale, F., Michiara, M., Tumino, R., Mangone, L., Falcini, F., Ferretti, S., Filiberti, R. A., Marani, E., Caiazzo, A. L., Iannelli, A., Sensi, F., Piffer, S., Gentilini, M., Madeddu, A., Colanino, A. Z., Maspero, S., Candela, P., Stracci, F., Tagliabue, G., Rugge, M., Baili, P., Minicozzi, P., Sant, M., Tereanu, C., Francisci, S., Tavilla, A., Pierannunzio, D., Rossi, S., Santaquilani, M., Knijn, A., Pildava, S., Smailyte, G., Calleja, N., Agius, D., Johannesen, T. B., Rachtan, J., Gózdz, S., Blaszczyk, J., Kepska, K., Lacerda, G. F. D., Bento, M. J., Miranda, A., Diba, C. S., Žagar, T., Almar, E., Larrañaga, N., Munain, A. L. D., Torrella-Ramos, A., García, J. M. D., Marcos-Gragera, R., Sanchez, M. J., Navarro, C., Salmeron, D., Moreno-Iribas, C., Galceran, J., Carulla, M., Mousavi, M., Bouchardy, C., Ess, S. M., Bordoni, A., Konzelmann, I., Rashbass, J., Gavin, A., Brewster, D. H., Huws, D. W., Ho, V. K., & Benhamou, E.
- Affiliations
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Istituto Superiore di Sanità (IT)
- National Cancer Registry (IE)
- Finnish Cancer Registry (FI)
- Netherlands Comprehensive Cancer Organisation (NL)
- Institute of Oncology Ljubljana (SI)
- Queen's University Belfast (GB)
- Policlinico Universitario di Catania (IT)
- Institut Scientifique de Santé Publique (BE)
- Public Health England (GB)
- Instituto de Salud Pública de Navarra (ES)
- Corresponding author
- Gatta, Gemma
- ORCID
- Gatta, Gemma
- Capocaccia, Riccardo
- Botta, Laura
- Mallone, Sandra
- Comber, Harry
- Dimitrova, Nadya
- Leinonen, Maarit K
- Siesling, Sabine
- Visser, Otto
- Anderson, Lesley A
- Stiller, Charles A
- Trama, Annalisa
- Dušek, Ladislav
- Mägi, Margit
- Paapsi, Keiu
- Malila, Nea
- Troussard, Xavier
- Guizard, Anne-Valérie
- Bouvier, Anne-Marie
- Arveux, Patrick
- Maynadié, Marc
- Woronoff, Anne-Sophie
- Robaszkiewicz, Michel
- Baldi, Isabelle
- Monnereau, Alain
- Colonna, Marc
- Molinié, Florence
- Grosclaude, Pascale
- Luttmann, Sabine
- Nennecke, Alice
- Mazzoleni, Guido
- Serraino, Diego
- Vitale, Francesco
- Tumino, Rosario
- Falcini, Fabio
- Ferretti, Stefano
- Filiberti, Rosa Angela
- Piffer, Silvano
- Tagliabue, Giovanna
- Rugge, Massimo
- Baili, Paolo
- Minicozzi, Pamela
- Sant, Milena
- Francisci, Silvia
- Tavilla, Andrea
- Pierannunzio, Daniela
- Rossi, Silvia
- Santaquilani, Mariano
- Knijn, Arnold
- Pildava, Santa
- Calleja, Neville
- Rachtan, Jadwiga
- Miranda, Ana
- Žagar, Tina
- Almar, Enrique
- Larrañaga, Nerea
- García, José María Díaz
- Navarro, Carmen
- Bouchardy, Christine
- Ess, Silvia M.
- Gavin, Anna
- Brewster, David H
- Huws, Dyfed Wyn
- Ho, Vincent KY
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 18
- Issue
- 8
- Pages
- 1022-1039
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2729284305
- Cited by
- 516
- References
- 22
- Citations by year
- 2026: 60 · 2025: 82 · 2024: 81 · 2023: 71 · 2022: 64 · 2021: 52 · 2020: 47 · 2019: 27 · 2018: 24 · 2017: 6
- FWCI
- 12.46
- Type
- journal article
- Language
- en
- Update notices
- erratum (2017-08-01)
- Open access
- bronze
- doi.org
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- OAR@UM (University of Malta) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion, other-oa)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion, cc-by)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- European Commission through the Consumers, Health, Agriculture and Food Executive Agency (Grant No. 2000111201)
- Topics
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advances in Oncology and Radiotherapy
- Health Sciences › Medicine › Oncology › COVID-19 and healthcare impacts
- Keywords
- rare tumor, cancer incidence, cancer survival, cancer registry, incidence trends, sarcoma, Europe, referral patterns, healthcare resource allocation, cancer care costs
- MeSH terms
- Cancer Care Facilities, Delivery of Health Care, Europe, Female, Hospitalization, Humans, Male, Neoplasms, Registries, Incidence, Survival Rate, Rare Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
